Compare Organon & Co. Common Stock (OGN) vs SPDR Kensho Final Frontiers ETF (ROKT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs SPDR Kensho Final Frontiers ETF — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while SPDR Kensho Final Frontiers ETF trades at $100.25 (market cap $167.17M). The key difference: Organon & Co. Common Stock is far larger — about 21.7× SPDR Kensho Final Frontiers ETF's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while SPDR Kensho Final Frontiers ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and SPDR Kensho Final Frontiers ETF for 14 Days on average.
| OGN | ROKT | |
|---|---|---|
Market Cap | $3.62B | $167.17M |
Volume | 2,892,999 | 167,750 |
Sector | Health | Sector/Thematic |
52-Week High | $13.81 | $136.68 |
52-Week Low | $5.70 | $72.93 |
Typical Hold Time | 0 Days | 14 Days |
Enterprise Value | $11.04B | — |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
ROKT (SPDR S&P Kensho Final Frontiers ETF) trades at $101.88, down 1.0% today, with a bearish technical outlook showing 17 sell signals versus 2 buy signals. The ETF provides diversified exposure to aerospace and defense companies, though key financial ratios are currently unavailable. Recent news highlights growing investor interest in space-related investments through diversified vehicles like ROKT rather than individual space stocks.
The ETF offers efficient exposure to the final frontiers theme but faces challenges from high operational costs and profitability timelines in the space sector. Current bearish technical indicators suggest near-term pressure, while long-term growth potential in aerospace and defense remains supported by industry developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About SPDR Kensho Final Frontiers ETF
SPDR Kensho Final Frontiers ETF seeks exposure to companies supporting exploration of outer space and the deep sea. Its holdings include businesses involved in aerospace, defense, communications, research, and related technologies.
Read more on ROKT →
